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Abstract
Metabolic stability of the new antimalarial drug leads is determined using Human Liver Microsome (HLM) and 
specific cytochrome P450 enzyme (CYP2C8) taking the clinically used antimalarial drug chloroquine as a positive 
control. Experiment is done using standard methods. All the assays were conducted in 0.5 M phosphate buffer at pH 
7.4. In general the metabolic reaction was initiated by adding 1 mM NADPH and 0.5 mg of enzyme. Incubations were 
done with time frequency of 0 hr, 1 hr, and 2 hrs at 37°C and the reactions were terminated by adding acetonitrile in the 
equal amounts of the assay mixture taken. The samples were centrifuged for 15 minutes at 10,000×g at 4°C and an 
aliquot of the supernatant was subjected to analysis using HPLC as well as LC-MS to confirm the masses of the drug 
and/or metabolite(s), if any. While chloroquine was found to be metabolized in a predictable manner by both HLM and 
CYP2C8, the drug leads were metabolically stable at similar experimental conditions. This study demonstrated that the 
new drug leads are worth conducting further preclinical evaluations.
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Introduction
With the arrival of new combinational drug synthesis, the need for 
an expeditious evaluation of drug safety has become a paramount topic 
in drug discovery. The duration and impact of drug discovery revolving 
around drug absorption, distribution, metabolism and excretion will be 
evaluated according to their determined metabolic stability. The major 
organ for drug metabolism is liver that contains major drug metabolizing 
enzyme called Cytochrome P450 (CYP) system [1]. Drug metabolism 
refers to the susceptibility of compounds to biotransformation that 
depends on the presence of groups in the molecule those are open to 
enzyme catalyzed transformation [2]. Drug metabolism can be divided 
into two phases, Phase I and phase II. Phase I involves oxidation, 
reduction and hydrolysis reactions, which are catalyzed by the CYP and 
flavin containing monooxygenases (FMOs) whereas Phase II involves 
conjugation reactions catalyzed by metabolic enzymes like UDP-
glucuronyltransferases (UGTs) and sulfotransferases [3,4]. 
Recognizing the metabolites of drugs is of paramount importance in 
drug discovery and development. The identification of drug metabolites 
in the early stages of the drug discovery is important in the development 
processes. The analytical tools like Liquid Chromatography-Mass 
Spectrometry (LC-MS) and HPLC play prominent role in these 
processes. Through this process of identification, the pharmacokinetic 
profiles can be assessed that are highly significant in detecting safety 
and efficacy of the drug leads before they are progressed to the clinical 
trials. 
The investigation for metabolites take an advantage of the fact 
that majority of drug metabolites can be classified as predictable as 
they are formed from common accepted biotransformation reactions. 
However, there are many other illustrations of primary metabolites 
that are formed from uncommon reactions and are, therefore, not 
easily predictable. Molecular masses of predicted metabolites (m/z 
values) can be estimated based on mass shifts from the parent drug. For 
example, Chloroquine is the major antimalarial drug that used in the 
treatment and prophylaxis of malaria, the protonated molecular mass 
of the metabolite of chloroquine, desethylchloroquine (DCQ), is 292 
m/z to that of the parent drug 320 m/z. Evaluation of some expected 
metabolites can be achieved by the acquisition of the complete MS 
spectrum using various MS instruments and also by Extracted Ion 
Chromatography (EIC) [4,5]. Using LC/MS, Clarke (2001) defined 
broadly the approaches for the identification of metabolites in biological 
matrices. After identifying the unknown metabolite ion peaks, further 
investigation to achieve detailed information on the pathways for the 
structure evaluation is done by multistage product ion scans [6,7].
The main purpose of the present study was to determine the 
metabolic stability of a series of newly discovered cyclen bisquinoline 
antimalarial drug leads [8] and related compounds (Figure 1) by RP-
HPLC and LC-MS techniques. Compound B was shown to be highly 
effective antimalarial agent both in vitro and in vivo and was found to 
work by inhibiting β-hematin formation [8]. This lead structure fulfilled 
few important criteria for a new drug lead: 1) it is a 4-aminoquinoline 
derivative that are the most trusted class of antimalarials, 2) active 
against chloroquine-resistant as well as multidrug resistant isolates of 
Plasmodium falciparum, 3) simple pharmacophore structure that will 
afford low cost manufacturing, and 4) it also showed oral efficacy in 
mice model. All these features warranted further preclinical studies 
with these leads and related newly synthesized compounds as shown 
in Figure 1. Compounds A, C, D and E were also shown to have potent 
in vitro antimalarial activity and also serve as drug leads (manuscript is 
under preparation). The present study was thus aimed at determining 
the in vitro metabolic stability and identifying potential metabolites by 
HPLC and LC-MS techniques using HLM and CYP enzymes. The study 
was designed based on the known metabolic pathway of the related 
clinically used drug chloroquine (CQ) [9-12] and thus utilized both 
pooled human liver microsomes as well as specific isozyme CYP2C8 
(Figure 1). 
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Materials and Methods
Materials
Chloroquine diphosphate purchased from Pfaltz & Bauer. NADPH, 
anhydrous with assay 93-100% (HPLC), was purchased from Sigma 
Aldrich. 0.5 M Potassium phosphate buffer pH 7.4 was purchased from 
BD Gentest. Human Liver Microsome (HLM) was purchased from BD 
Bioscience and Corning. Human cDNA expressing CYP 450 and 2C8 
were purchased from XenoTech and Corning. In the solvent system 
methanol Triethylamine, DMSO, and acetonitrile were purchased from 
Fisher Scientific. Dibasic anhydrous sodium phosphate and phosphoric 
acid were purchased from Fisher Scientific. Deionized water used was 
further purified by filtration and degassing. The drug leads mentioned 
in the Figure 1 were synthesized.
Chromatographic conditions
HPLC Method 1: The HPLC system used was Agilent 1100 series 
(Hewlett-Packard-Strasse 8, 76337 Waldbronn Germany), equipped 
with a pump, Diode array detector with UV lamp operated at variable 
wavelengths, autosampler, and thermostat. Data Acquisition was 
performed using Open Lab CDS Chem Station Edition software 
package with A.01.02 version implemented in the chromatographic 
system. Detection at 250 nm and 280 nm was standard. The stationary 
phase consisted of Waters X-Bridge C-18 column (4.6 mm×150 mm, 
5.0 µm particle size, pore volume 0.76 cm3/g) purchased from Waters 
Corporation (34 Maple Street, Milford, Massachusetts 01757-3696 
U.S.A). It was operated at constant temperature of 25°C on both ends 
of the column. 
The mobile phase consisted of a mixture of 0.04% formic acid in 
water (i), acetonitrile (ii) and methanol (iii) in a gradient elution mode 
as shown in Table 1 [9]. The flow rate was maintained at 1.0 ml/min.
LC-MS system used was Shimadzu prominence LC 20AT, equipped 
with Degasser (DGU- 20A5), Auto sampler (SIL-20AHT), Refractive 
index detector (RID-10A), Diode array detector (SPDM-20M20A), 
Fraction collector (FRC-10A) and a mass spectrometer (LC-MS 2020). 
Data Acquisition was performed by Lab Solutions Real Time Analysis 
Software, implemented in the chromatographic system. 
HPLC Method 2: Chromatographic separation of CQ, drug lead B, 
and metabolites was successfully achieved on a Waters X-Bridge C-18 
column (4.6 mm×250 mm, 5.0 µm particle size, part no. 186003117) 
purchased from Waters Corporation in an isocratic separation mode 
with mobile phase consisting of 0.1% of triethylamine in methanol 
and 0.02 M dibasic sodium phosphate (anhydrous) at pH 3.5 adjusted 
with Phosphoric Acid  in the ratio of (60:40, v/v). The flow rate was 
maintained at 1.0 ml/min, the column oven temperature at 40°C and the 
effluent was monitored at 325 nm (based on the λ). The peak purity data 
were obtained using Photodiode Array (PDA) detector in the sample 
chromatograms. The method was found linear over the concentration 
range of 3.5–200.1 µg/ml (R2=0.99) for drug lead B.
General procedure
The method used to determine the metabolism was a modified 
method obtained from BD Bioscience, which is summarized here. 
Metabolic stability study of a drug can be determined by treating it 
with the liver enzyme that correlates with the in vivo conditions. The 
assay mixture is prepared by the combination of substrate (0.01 mM 
to 0.5 mM), enzyme (0.5 mg), buffer (0.5 M), and 1 mM NADPH 
cofactor. The order of addition of the assay component also plays a 
major role in the stability study. Metabolism can be initiated by pre-
warming or incubating the substrate, buffer, and the cofactor to 37°C 
and then adding liver microsomes or CYP2C8 to the mixture. It is 
customary that the assay mixture should be thoroughly mixed. After 
the preparation of the Total Assay Mixture (TAM), required volume 
of the sample is collected at different time intervals. The reaction 
is then terminated using acetonitrile in equal volumes as that of the 
sample solution collected. The samples are then transferred into the 
microcentrifuge tubes, vortexed for 2 minutes and then centrifuged at 
10,000×g for 15 minutes. The purpose of centrifugation is to remove the 
protein. The sample solution is then separated from the protein pellet 
by taken the supernatants. These supernatant solutions are transferred 
into the HPLC auto sampler vials and are analyzed according to the 
analytical method.
Metabolic stability in HLM using HPLC Method 1
The HLM used was pooled and prepared from freshly frozen human 
tissues which were tested negative for pathogens using PCR. The HLM 
used in this study was comprised of 330 pmoles/mg of total P450 and 
420 pmoles/mg cyt. b5. It is a mixture of CYP1A2, 2A6, 2B6, 2C8, 2C9, 
2C19, 2D6, 2E1, 3A4, 4A11, FMO, UGT1A1, UGT1A4, and UGT1A9 
where the enzyme activity of CYP2C8, 3A4, and 2D6 was 82, 3200, and 
110 pmoles/(mg×min) respectively. The volume of the enzyme per vial 
was 0.5 ml and the protein content was 20 mg/ml in 250 mM sucrose. 
All the incubations were performed in duplicates. Therefore, all 
together there were 6 samples for each drug, one blank and 6 samples 
of the positive control. The total experiment with 5 drugs has about 
65 samples. All the components used in the TAM are shown in Table 
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Figure 1: Chemical structures of chloroquine and the main drug leads A, B, C, D, and E.
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2 with their volumes. All the ingredients in the TAM are taken in the 
order of their serial number (Table 2).
5 mM of the substrate stock solutions were prepared by dissolving 
in DMSO. The buffer used was 0.5 M potassium phosphate pH 7.4 (BD 
Biosciences Cat No. 451201). TAM was prepared by adding 10 µl of 
the sample, 200 µl of the buffer solution, 598 µl of water, and 167 µl of 
NADPH. It was then pre-incubated for 2 minutes in a shaking water bath 
and 25 µl of the enzyme was added to initiate the reaction. The capped 
tube was mixed thoroughly by inverting a couple of times. Immediately, 
at time t=0 hr, 300 µl of the TAM was taken into a centrifuge tube 
and the reaction was terminated by placing it on ice bath and adding 
300 µl of acetonitrile. The remaining TAM was warmed in a shaking 
water bath at 37°C for 2 hrs and the same procedure is followed for the 
samples at time t=1 hr and t=2 hr. The incubation mixtures were then 
centrifuged for 15 minutes at 10,000×g at 4°C. About 500 µl aliquots 
of the supernatant were collected and were subjected to analysis using 
the HPLC conditions as shown in Table 1. After running HPLC the 
samples were frozen and then lyophilized to remove the solvent. The 
dried samples were then dissolved in methanol and water (50:50 v/v) 
for LC-MS analyses. 
Metabolic stability in CYP2C8 using HPLC method 1
The CYP enzyme is comprised of a human CYP2C8 and human 
CYP-reductase co-expressed in Escherichia coli. The concentration of 
the CYP P450 is 1.0 nmol/ml and its protein concentration is 10.0 mg/
ml. All the assays were conducted in 0.2 M phosphate buffer at pH 7.4. 
One blank for each sample A, B, C, D, and E was prepared by adding 
180 µl of the sample in 1620 µl of the buffer. The total assay mixture 
contained 25 pmoles/ml of CYP2C8 and 0.5 mM of sample as shown 
in the table 3. 
180 µl of  Sample, 1275 µl buffer, and 300 µl of 1 mM NADPH 
was taken into a reaction flask and was pre-incubated for 2 minutes. 
The reaction was initiated by adding 45 µl enzyme. Incubations were 
done with increasing time (t=0 hr, 1 hr, 2 hrs) at 37°C. Immediately at 
time=0 hr, 300 µl of the assay mixture was pipetted into a centrifuge 
tube and 300 µl of acetonitrile was added to it to stop the reaction. All 
the samples were done in triplicates. Therefore, all together there were 9 
samples for each drug, one blank and 9 samples of the positive control. 
The total experiment with 5 drugs had about 95 samples. 
The remaining TAM was incubated for 1 hr and 2 hrs, same 
procedure of sampling was followed as mentioned in the HLM section. 
Then the samples were centrifuged for 15 minutes at 10,000×g at 
4°C. An aliquot about 500 µl of the supernatant fraction were collected 
and subjected to analysis using the above HPLC conditions as shown 
in Table 1. The retention times were noted and the amounts of drugs 
metabolized were calculated according to their percentage peak area 
using the equation: % peak area of the metabolite/(% peak area of the 
drug+% peak area of the metabolite). After running HPLC the samples 
were frozen and then lyophilized to remove the solvent. The dried 
samples were then dissolved in methanol and water (50:50 v/v) and 
tested for their mass. The mass of the drug and the metabolite were 
determined by using LC-MS. 
Metabolic stability in HLM and CYP2C8 using HPLC method 
2
To verify the metabolic stability results using HPLC method 1, 
HPLC method 2 was carried out using drug lead B, and CQ as a positive 
control. For that we prepared sample, standard and blank for our drug 
lead B and CQ in duplicates as mentioned in the following Table 4. 
All the ingredients in the TAM were taken in the order of their serial 
number (Table 4).
 Sample stock solutions of Chloroquine diphosphate and Cylen 
Bisquinoline Hydrochloride Salt were prepared by dissolving in water. 
0.5 M potassium phosphate pH 7.4 (BD Biosciences Cat No. 451201) 
was used as a buffer. Sample solutions were prepared by adding 20 µl of 
substrate, 400 µl of the buffer solution, 200 µl of the NADPH solution 
and 1355 µl of water. Standard solutions were prepared by adding 20 µl 
of Substrate, 400 µl of the buffer solution and 1580 µl of water. Blank 
solutions were prepared by adding 400 µl of the buffer solution, 200 µl 
of the NADPH solution and 1375 µl of water.
All the above solutions were then pre-incubated for 5 minutes in 
a shaking water bath at 37°C. Reaction was initiated by adding 25 µl 
of the enzyme (from Corning HLM-452161 and CYP2C8-456252). 
These TAMs were mixed thoroughly by inverting a couple of times 
and returned to the water bath. Immediately, at time t=0 hr, 500 µl 
of the TAM was taken into a centrifuge tube and the reaction was 
terminated by placing it on ice bath and adding 500 µl of acetonitrile. 
The remaining TAMs were warmed in a shaking water bath at 37°C for 
2 hrs and the same procedure was followed for the samples at time t=1 
hr and t=2 hr. The incubation mixtures were then centrifuged for 15 
minutes at 10,000×g at 4°C. About 500 µl aliquots of the supernatant 
were collected and subjected to analysis using the HPLC method 2. 
After running HPLC the samples were frozen and then lyophilized to 
remove the solvent. The dried samples were then dissolved in methanol 
and water (50:50 v/v) for LC-MS analyses. 
Results and Discussion
HPLC Method 1
Results using HLM: Under the provided experimental conditions 
S. No. Ingredients Volume (in 1 mL of total assay mixture) Final Concentration
1 Sample 10 µl 0.05 mM
2 Buffer (0.5 M) 200 µl 100 mM
3 DI Water 598 µl -
4 NADPH 167 µl 1 mM
5 Enzyme 25 µl 0.5 mg
Table 2: Total assay mixture using HLM.
S. No. Ingredients Volume (TAM) Final Concentration
1. Sample 180 µl 0.5 mM
2. Buffer 1275 µl 0.2 M
3. NADPH 300 µl 1m M
4. Enzyme 45 µl 25 pmoles/ml
Table 3: Total assay mixture using CYP 2C8.
S. No. Ingredients
Sample Standard Blank
Volume, 2 mL 
of  TAM
Final 
Concentration
Volume, 2 
mL of  TAM
Volume, 2 
mL of  TAM
1 Substrate (1 mM) 20 µl 0.01 mM 20 µl ---
2 Buffer (0.5 M) 400 µl 100 mM 400 µl 400 µl
3 NADPH 200 µl 1 mM --- 200 µl
4 DI Water 1355 µl --- 1580 µl 1375 µl
5 Enzyme 25 µl 0.5 mg --- 25 µl
Table 4: Total assay mixture using HLM and CYP2C8.
Time (Min)/solvent 0.04% formic acid in Water Acetonitrile Methanol
0 96 0 4
10 64 30 6
12 4 90 6
Table 1: Mobile phase for metabolic stability study: Gradient elution mode.
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it was observed that CQ was metabolized in a predictable manner by 
HLM into the metabolite DCQ; contrarily all our experimental drug 
leads were metabolically stable. Not only was the metabolite for CQ 
identified in HPLC (Figure 2) but also in MS (Figure 7) reconfirming 
our results. Both drug (320 m/z) and metabolite masses (292 m/z) 
were observed in the LC-MS analysis of the samples. According to 
the area under curve ratios, CQ was converted to about 5.12% of its 
N-deethylated metabolite after 1 hour of incubation and 6.42% after 
2 hours of incubation. On the other hand, the drug leads A (523m/z), 
B (495m/z), C (561m/z), D (885 m/z), and E (619 m/z) were found to 
be metabolically stable in both HPLC and LC-MS analyses. A sample 
chromatogram of CQ and compound B are shown in the Figures 2 and 
3. The retention times and the peak areas of the drug leads A, B, C, D, E 
and CQ obtained at time t =1 hr and 2 hr are shown in the Table 5. At 
time t=0 min there was no metabolism with any of the drug samples. 
At time t=1 hr CQ showed some metabolism whereas the drug leads 
were stable. There was no evidence of any metabolite mass of any of 
the drug leads when they were analyzed by LC-MS. The molecular ion 
peaks (m/z) were similar to those of their molecular weights (Figures 2 
and 3) (Table 5). 
Results using CYP2C8: As shown in Figure 4, about 10.33% of CQ 
was transformed into DCQ after 1 hour of incubation and 12.26% after 
2 hours of incubation, whereas the drug lead B was stable as shown in 
Figure 5. The drug leads A (523 m/z), B (495 m/z), C (561 m/z), D (885 
m/z), and E (619 m/z) were metabolically stable at similar experimental 
conditions. The retention times of the drugs A, B, C, D, E and CQ 
obtained at time t=0 were 8.136, 5.971, 4.869, 5822, 5.817 and 6.998, 
respectively, and no metabolite peak was evident. The retention times 
of the drug leads and the CQ at time t=1 hr and t=2 hr is shown in the 
Table 6. All the samples were estimated in triplicates and the results 
shown are the average of the three trials (Figures 4 and 5) (Table 6).
With these results, it was confirmed that CYP2C8 has an important 
role in the metabolism of chloroquine and the drug leads were 
metabolically stable. The experiment was extended up to 24 hours for 
the drug leads and consequently no metabolism was observed. The 
drug masses were confirmed by MS (Figures 6-9).
HPLC Method 2
Results using HLM: Under provided experimental conditions using 
HPLC method 2, similar results were obtained, CQ was metabolized 
by HLM into the metabolite DCQ and contrarily the drug lead B was 
metabolically stable. The metabolite was identified by HPLC and also 
by LC-MS reconfirming the results shown in method 1. Both drug (320 
m/z) and metabolite (292 m/z) masses were observed in the LC-MS 
analysis of the samples. According to the area under curve ratios, CQ 
was converted to about 4.29% of its N-deethylated metabolite after 1 
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Figure 2: HPLC chromatogram of chloroquine at time A) 0 hour and B) 2 hour 
using HLM.
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Figure 3: HPLC chromatogram of drug lead B at time A) 0 hour and B) 2 hour 
using HLM.
Time t=1 hr Time t=2 hr
Drugs RT Metabolism MS- (m/z) RT Metabolism MS- (m/z)
A 8.136 NO 523 8.141 NO 523
B 5.737 NO 495 5.791 NO 495
C 4.869 NO 561 4.877 NO 561
D 5.818 NO 885 5.822 NO 885
E 5.822 NO 619 5.831 NO 619
CQ/DCQ 6.801/6.485 YES 320, 292* 6.817/6.510 YES 320, 292*
*Percentage of the metabolite formation was calculated according to the 
obtained percentage peak areas of the metabolite and the drug. The percent of 
CQ metabolized using HLM at time t=1 hr and 2 hrs was 5.12% and 6.146%, 
respectively.
Table 5: Data obtained from HPLC and MS for the drugs using HLM.
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Figure 4: HPLC chromatogram of chloroquine at time A) 0 hour and B) 2 hour 
using CYP2C8.
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Figure 5: HPLC chromatogram of drug B at time A) 0 min and B) 2 hour using 
CYP2C8.
Time t= 1 hr Time t= 2 hr
Drugs RT Metabolism MS- (m/z) RT Metabolism MS-(m/z)
A 8.126 NO 523 8.136 NO 523
B 5.973 NO 495 5.944 NO 495
C 4.875 NO 561 4.869 NO 561
D 5.819 NO 885 5.822 NO 885
E 5.821 NO 619 5.817 NO 619
CQ/DCQ 7.017/6.784 YES 320, 292* 7.011/6.772 YES 320, 292*
*The percent of CQ metabolized using CYP2C8 at time t=1hr and 2hrs was 12.26% 
and 10.33%, respectively. 
Table 6: Data obtained from HPLC and MS for the drugs using CYP2C8.
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hour of incubation and 6.61% after 2 hours of incubation. On the other 
hand, the drug leads B (495 m/z) was found to be metabolically stable in 
both HPLC and LC-MS analyses. A sample chromatogram of CQ and 
compound B are shown in Figure 10C and Figure 11C, respectively. The 
retention times and the peak areas of the drug lead B and CQ obtained 
at time t=1hr and 2hr are shown in the Table 7.
Results using CYP2C8: Under provided experimental conditions 
using HPLC method 2, similar results were obtained, CQ was 
metabolized by CYP2C8 into the metabolite DCQ and contrarily the 
drug lead B was metabolically stable. Using CYP2C8 about 2.23% of CQ 
was transformed into DCQ after 1 hour of incubation and 2.89% after 2 
hours of incubation. The drug lead B (495 m/z) was metabolically stable 
at similar experimental conditions (Figure 11D). The retention times 
of the drug lead B and the CQ at time t=1 hr and t=2 hr are shown in 
the Table 8. All the samples were estimated in duplicates and the results 
shown are the average of the two trials (Figures 10 and 11) (Table 8). 
According to the results obtained from HPLC method I and II, it 
was confirmed that both HLM and CYP2C8 has an important role in the 
metabolism of chloroquine whereas, all drug leads were metabolically 
stable to these enzyme. 
Discussion
The in vitro metabolism of the new drug leads compared to the 
positive control chloroquine in the presence of HLM and cDNA 
expressing CYP2C8 have been demonstrated in this study. In the 
pharmacokinetic studies of CQ, Frisk-Holmberg [6,7] reported the 
single dose kinetics of CQ and its major metabolite DCQ in healthy 
subjects and identified that CQ is dealkylated into two main metabolites, 
N-desethylchloroquine (DCQ) and N-bis-desethylchloroquine 
(BDCQ). Identification of metabolites is done by LC-MS. Mass 
spectrometers help in separating the compounds from each other using 
the difference in mass-to-charge ratio (m/z) of ionized compounds.
In blood and plasma, the concentration of DCQ was detected 
up to 20 to 50% of those of the parent compound CQ, whereas the 
conversion to BDCQ was <10% [6,7]. It is known that CYPs are major 
drug metabolizing enzyme system. Ofori- Adjei and Ericsson [13] 
estimated that 30 to 50% of an administered dose of chloroquine is 
metabolized by the liver via cytochrome P450 enzymes. Identification 
of the major enzymes, associated with drug’s metabolism therefore 
started by evaluating and identifying the role of CYP isoforms. Xue-
Qing Li et al. [14] identified human CYPs that metabolize anti-parasitic 
drugs using three approaches, (a) Relative Activity Factor (RAF), (b) 
correlation analysis of their activity, and (c) inhibitors diagnostics. They 
reported that the major CYPs involved in the metabolism are CYP 
isoforms 2C8, 3A4, and 2D6. The RAF approach is used significantly 
to bridge the gap between liver microsomes and recombinant systems. 
It also estimates the individual P450 contributions to drug metabolism 
[15,16]. Using the same approach, Projean et al. [9] also reported 
that CYPs 2C8, 3A4, and 2D6 are the main isoforms catalyzing DCQ 
formation. This was the first investigation of CQ metabolism in HLM 
and they identified that CYP2C8 and CYP3A4 contributes collectively 
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Figure 7: MS spectrum showing chloroquine and N-desethylchloroquine 
masses at t=2hr using HLM. Similar chromatogram was observed when the 
experiment was conducted using CYP2C8.
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Figure 8: MS spectrum showing drug lead B standard.
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Figure 9: MS spectrum showing drug lead B mass at t=2 hr using HLM. 
Similar chromatogram was observed when the experiment was conducted 
using CYP2C8.
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Figure 6: MS spectrum showing chloroquine standard.
Time t=1 hr Time t=2 hr
Drugs RT Metabolism MS- (m/z) RT Metabolism MS- (m/z)
B 13.135 NO 495 13.10 NO 495
CQ/DCQ 5.460/4.480 YES 320, 292* 5.470/4.508 YES 320, 292*
*The percent of CQ metabolized using HLM at time t=1 hr and 2 hrs was 4.29% 
and 6.61%, respectively 
Table 7: Data obtained from HPLC and MS for the drug using HLM.
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Time t=1 hr Time t=2 hr
Drugs RT Metabolism MS- (m/z) RT Metabolism MS- (m/z)
B 13.145 NO 495 13.129 NO 495
CQ/DCQ 5.486/4.533 YES 320,292* 5.432/4.517 YES 320,  292*
*The percent of CQ metabolized using CYP2C8 at time t=1 hr and 2 hrs was 12.26% and 10.33%, respectively
Table 8: Data obtained from HPLC and MS for the drugs using CYP2C8.
more than 80% of the total CQ N-desethylation over a wide range of 
concentrations. Their study suggested that, in humans, the therapeutic 
concentration of CQ that is metabolized into DCQ is primarily via 
CYP2C8 and CYP3A4, whereas 2D6 plays a significant role when CQ 
concentrations are low. This study also shows that CYPs, 2C8, and 3A4 
constitute low-affinity and high-capacity systems, whereas CYP2D6 has 
higher affinity but a significantly lower capacity. Among these CYP2C8 
represents approximately 5% of the total hepatic CYPs and metabolizes 
drugs that are amides or weak bases with two hydrogen bond acceptors 
[11,17,18]. Kim et al. [10] also identified that CYP2C8 and 3A4/5 are 
involved in metabolism of CQ into desethylchloroquine in human liver 
microsomes. This was also consistent with the previous data obtained 
from Ducharme and Farinotti [19]. Previous studies show that the 
relative content of CYP 3A4, 2C8 and 2D6 in 60 human samples are 
29%, 18%, and 2%, respectively [20]. Based on these literature evidence, 
HLM and CYP2C8 were obvious selection to study the in vitro 
metabolism stability of the new drug leads due to the similarity of the 
structures and activity of the lead compounds with chloroquine. While 
chloroquine was metabolized by both HLM and CYP2C8 considerably, 
all these new drug leads were metabolically stable. 
In the Figure 10, the HPLC chromatograms clearly showed that CQ 
was metabolized and there was an additional peak before the parent 
peak which was absent in blank and control sample, partially confirms 
the metabolism of chloroquine. Moreover, when the samples were 
tested with LC-MS (Figure 7), positive control chloroquine sample at 
time t=2 hrs gave two ion peaks, one at 320 m/z and another at 292 m/z, 
which confirms the metabolism of the drug. 
In the Figure 11, the HPLC chromatograms clearly showed that 
drug lead B was not metabolized but the appearance of an additional 
peak before the parent peak in blank and control sample confirms the 
presence of impurity in drug lead B. The spectrum (Figure 9) obtained 
 
17.5
15
12.5
10
7.5
5
2.5
0
17.5
15
12.5
10
7.5
5
2.5
0
17.5
15
12.5
10
7.5
5
2.5
0
17.5
15
12.5
10
7.5
5
2.5
0
10                                   min
10                                   min
10                                   min
10                                   min
DAD1 A, Sig=325,4 Ref=off (46.D) AmAU
mAU
mAU
mAU
DAD1 A, Sig=325,4 Ref=off  (56.D) B
DAD1 A, Sig=325,4 Ref=off  (57.D)
C
8
6
4
2
0
2
.4
9
5
 (
B
la
n
k
)
4.
50
8 
(M
et
ab
ol
it
c)
5
.4
7
0
(C
Q
)
DAD1 A, Sig=325,4 Ref=off  (57.D)
mAU
0                                          min
8
6
4
2
0
2
.4
7
4
 (
B
la
n
k
)
4.
51
7 
(M
et
ab
ol
it
c)
DAD1 A, Sig=325,4 Ref=off  (59.D)
mAU
0                                       min
8
6
4
2
0
DAD1 A, Sig=325,4 Ref=off  (56.D)
mAU
0                                       min
5
.4
3
2
(C
Q
)
DAD1 A, Sig=325,4 Ref=off  (59.D)
D
CQ
8
6
4
2
0
DAD1 A, Sig=325,4 Ref=off  (46.D)
mAU
0                                           min
2
.5
0
5
Blank CQ
5.
43
0
Figure 10: HPLC chromatograms of chloroquine. A) Blank (NADPH, Enzyme & Buffer), B) CQ (Control without Enzyme), C) CQ in HLM (t=2 hr), and D) CQ in 
CYP2C8 (t=2 hr).
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from LC-MS showed the ion peak of the drug lead B at time t=2 hrs as 
495 m/z, which confirms its molecular weight. Henceforth there is no 
metabolism of the drug lead B.
As discussed earlier, CYP enzymes provide information regarding 
the metabolites. Nebert and Russell [21] mentioned that there are 
270 different CYP gene families, and 18 of those gene families were 
recorded in mammals that encrypt 57 CYP genes in humans. Out of 
all CYP enzymes, CYP2C8, 3A4, and 2D6 are involved in Chloroquine 
metabolism. This was proven in our experiment where CYP2C8 
contributed to more than 10% of the total CQ N-desethylation over 
a 100 µM concentration [22]. It has low affinity and high capacity 
in metabolizing the chloroquine. Further investigations would be 
conducted utilizing more CYP isozymes at different concentration 
ranges and time intervals to identify any possible metabolic pathways 
for these drug leads in near future as a part of our continuous preclinical 
analysis. This study demonstrated a convenient method development 
and also a metabolic stability of the drug leads against most important 
CYP isozyme that is involved in the metabolism of standard drug 
chloroquine.
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